

## Special Issue

# Secondary Metabolites from Marine Molluscs: Chemistry, Biosynthesis, Synthesis and Bioactivity

### Message from the Guest Editor

The phylum Mollusca embraces a high diversity of species, which turned out to be of great interest to natural products chemists. Chemical studies unveiled a variety of unique scaffolds inspiring leading drugs currently in clinical trials. Thus, extending investigation on unexplored species is expected to reveal novel molecular architectures. Beyond the chemistry and pharmacological potential of molluscan metabolites, their crucial role in regulating chemo-ecological interactions has also been addressed. The majority of these molecules are obtained from food sources, but they can be biosynthesized *de novo*, or derived from symbiotic microorganisms. This Special Issue is open to contributions covering all aspects of chemistry, chemical ecology and pharmacological potential of secondary metabolites from molluscs; papers are welcome on: i) the discovery of novel bioactive compounds and their molecular targets; ii) the origin and the biosynthetic pathways by which these metabolites are produced; iii) their chemo-ecological role; iv) the synthetic strategies designed to overcome the supply issue for the metabolites themselves and to provide derivatives with improved potency.

### Guest Editor

Dr. Adele Cutignano

Institute of Biomolecular Chemistry, National Research Council,  
Pozzuoli, Italy

### Deadline for manuscript submissions

closed (31 August 2019)



## Marine Drugs

an Open Access Journal  
by MDPI

Impact Factor 5.4  
CiteScore 10.1  
Indexed in PubMed



[mdpi.com/si/14604](https://mdpi.com/si/14604)

*Marine Drugs*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[marinedrugs@mdpi.com](mailto:marinedrugs@mdpi.com)

[mdpi.com/journal/  
marinedrugs](https://mdpi.com/journal/marinedrugs)





# Marine Drugs

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.4  
CiteScore 10.1  
Indexed in PubMed



[mdpi.com/journal/  
marinedrugs](https://mdpi.com/journal/marinedrugs)



## About the Journal

### Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

---

### Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))